Updating the probability of study success for combination therapies using related combination study data

被引:1
|
作者
Graham, Emily [1 ,5 ]
Harbron, Chris [2 ]
Jaki, Thomas [3 ,4 ]
机构
[1] Univ Lancaster, STOR i Ctr Doctoral Training, Lancaster, England
[2] Roche Pharmaceut, Welwyn Garden City, England
[3] Univ Regensburg, Regensburg, Germany
[4] Univ Cambridge, MRC Biostat Unit, Cambridge, England
[5] Univ Lancaster, STOR i Ctr Doctoral Training, Lancaster LA1 4YF, England
基金
英国医学研究理事会; 英国工程与自然科学研究理事会;
关键词
Combination therapies; clinical trials; probability of success; Bayesian; assurance; CLINICAL-TRIALS; PHASE-II; TRASTUZUMAB; PERTUZUMAB; DOCETAXEL; POWER; END;
D O I
10.1177/09622802231151218
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Combination therapies are becoming increasingly used in a range of therapeutic areas such as oncology and infectious diseases, providing potential benefits such as minimising drug resistance and toxicity. Sets of combination studies may be related, for example, if they have at least one treatment in common and are used in the same indication. In this setting, value can be gained by sharing information between related combination studies. We present a framework that allows the study success probabilities of a set of related combination therapies to be updated based on the outcome of a single combination study. This allows us to incorporate both direct and indirect data on a combination therapy in the decision-making process for future studies. We also provide a robustification that accounts for the fact that the prior assumptions on the correlation structure of the set of combination therapies may be incorrect. We show how this framework can be used in practice and highlight the use of the study success probabilities in the planning of clinical studies.
引用
收藏
页码:712 / 731
页数:20
相关论文
共 50 条
  • [1] Pembrolizumab in mCRPC - Combination therapies as breakthrough to success?
    Plas, Stefan
    Pircher, Andreas
    Heidegger, Isabel
    CURRENT OPINION IN UROLOGY, 2023, 33 (06) : 458 - 471
  • [2] Clinical trial success rates of anti-obesity agents: the importance of combination therapies
    Hussain, H. T.
    Parker, J. L.
    Sharma, A. M.
    OBESITY REVIEWS, 2015, 16 (09) : 707 - 714
  • [3] Probability of Study Success (PrSS) Evaluation Based on Multiple Endpoints in Late Phase Oncology Drug Development
    Zhang, Zhen
    Lin, Yong
    Liu, Jingyi
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2023, 15 (03): : 675 - 688
  • [4] A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies
    Hirakawa, Akihiro
    Wages, Nolan A.
    Sato, Hiroyuki
    Matsui, Shigeyuki
    STATISTICS IN MEDICINE, 2015, 34 (24) : 3194 - 3213
  • [5] Bayesian multivariate probability of success using historical data with type I error rate control
    Alt, Ethan M.
    Psioda, Matthew A.
    Ibrahim, Joseph G.
    BIOSTATISTICS, 2022, 24 (01) : 17 - 31
  • [6] Comments on "A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies'
    Riviere, Marie-Karelle
    Zohar, Sarah
    STATISTICS IN MEDICINE, 2016, 35 (03) : 475 - 478
  • [7] Update on the role of ipilimumab in melanoma and first data on new combination therapies
    Maio, Michele
    Di Giacomo, Anna M.
    Robert, Caroline
    Eggermont, Alexander M. M.
    CURRENT OPINION IN ONCOLOGY, 2013, 25 (02) : 166 - 172
  • [8] Comments on 'A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies' Reply
    Hirakawa, Akihiro
    Sato, Hiroyuki
    STATISTICS IN MEDICINE, 2016, 35 (03) : 479 - 480
  • [9] Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study
    Tolaney, Sara M.
    Jhaveri, Komal
    Helsten, Teresa
    Puhalla, Shannon L.
    Conlin, Alison
    Dees, E. Claire
    Beeram, Muralidhar
    Chapman, Sonya C.
    Lithio, Andrew
    Litchfield, Lacey M.
    Goetz, Matthew P.
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [10] The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study
    Mahammedi, Hakim
    Planchat, Eloise
    Pouget, Melanie
    Durando, Xavier
    Cure, Herve
    Guy, Laurent
    Van-Praagh, Isabelle
    Savareux, Laurent
    Atger, Marc
    Bayet-Robert, Mathilde
    Gadea, Emilie
    Abrial, Catherine
    Thivat, Emilie
    Chollet, Philippe
    Eymard, Jean-Christophe
    ONCOLOGY, 2016, 90 (02) : 69 - 78